Hyderabad, Oct. 21 -- Nucelion Therapeutics, a wholly owned subsidiary of vaccine maker Bharat Biotech, on Wednesday announced a strategic collaboration with Hyderabad-based precision oncology company VeGen Bio to facilitate technology transfer, clinical manufacturing and commercial production of cell therapies, initially focusing on advancing a dual-target CAR-T therapy for multiple myeloma.
Multiple myeloma is a blood cancer associated with significant unmet medical needs and treatment-access challenges in India.
Under the agreement, Hyderabad- based Nucelion will undertake technology transfer and clinical- and commercial-stage manufacturing of VeGen Bio's lead candidate, VL-2511, which targets BCMA and CD19 antigens.
The companies aim...